Greer Murphy M.D., Ph.D.

Publication Details

  • Extended treatment with bupropion SR for cigarette smoking cessation JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY Killen, J. D., Fortmann, S. P., Murphy, G. M., Hayward, C., Arredondo, C., Cromp, D., Celio, M., Abe, L., Wang, Y., Schatzberg, A. F. 2006; 74 (2): 286-294

    Abstract:

    The authors present results of a randomized clinical trial of the efficacy of extended treatment with bupropion SR in producing longer term cigarette smoking cessation. Adult smokers (N = 362) received open-label treatment (11 weeks) that combined relapse prevention training, bupropion SR, and nicotine patch followed by extended treatment (14 weeks) with bupropion SR or matching placebo. Abstinence percentages were relatively high (week 11: 52%; week 25: bupropion, 42%; placebo, 38%; week 52: bupropion, 33%; placebo, 34%), but bupropion SR did not surpass placebo. Gender and baseline craving level were identified as significant, independent moderators of treatment response. Men were more likely to abstain than women (week 11: 59% vs. 43%, p = .001; week 25: 48% vs. 31%, p = .001; week 52: 39% vs. 27%, p = .01). Because most smokers suffer relapse with any current cessation treatment, the comparatively high abstinence percentages achieved in this trial are of interest.

    View details for DOI 10.1037/0022-006X.74.2.286

    View details for Web of Science ID 000237667500009

    View details for PubMedID 16649873

Stanford Medicine Resources:

Footer Links: